Why we should consider RNA-based NGS to identify NTRK gene
Both RNA-based and DNA-based NGS are capable of multiplexed assessment
for different fusion targets. However, RNA-based NGS is preferred for
identifying NTRK gene fusions, due to its capability to detect expressed
fusion transcripts directly, with more accurate breakpoint readout.
RNA-based NGS avoids the difficulties of sequencing larger intronic
regions associated with NTRK gene fusions. It also has a faster
sequencing process compare to DNA-based NGS. Its detection accuracy can
vary depending on the choice of library preparation methods, for
example, hybridization-based capture or amplicon-based approach.
Why choose Codex for NGS testing?
Codex provides comprehensive cancer screening using next-generation
sequencing (NGS) technology, which helps identify genetic mutations
associated with 523 cancer-related genes and 9 types of cancer. The
CoGenesis® Bioinformatics platforms allow comprehensive and accurate
profiling for data analysis. It provides AI-assisted matching of genomic
variants. The platform is fully scalable with shortened computation
time. It improves the query performance of complex biological queries.
Codex’s laboratory is using the latest sequencer – Illumina NextSeq
2000, for next-generation sequencing (NGS). It simplifies sequencing
workflows and minimizes the need for additional resources. Therefore,
sequencing turnaround time is reduced.
Codex Genetics applies a DNA and RNA hybridization-based approach for
detecting a broad range of NTRK gene fusions. This approach allows us to
detect a larger number of genes and genomic regions, while offering a
high level of sensitivity for detecting fusions with novel fusion